The MAPP research network: a novel study of urologic chronic pelvic pain syndromes

1Urologic chronic pelvic pain syndrome (UCPPS) encompasses two highly prevalent non-malignant urologic disorders, interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). UCPPS is primarily characterized by chronic and often debilitating pain in the pelvic region and/or genitalia and typically a spectrum of defects in bladder and lower urinary tract function.

2Numerous studies have been conducted over the past two decades to define the pathophysiology and natural history of UCPPS and to examine the efficacy of therapies. Many of those studies were supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH). The first NIDDK-sponsored pelvic pain clinical research network, the Interstitial Cystitis Database study (ICDB) was initiated in 1991. This five-year prospective cohort study collected data on more than 600 persons and characterized them across demographic and clinical characteristics, including bladder biopsy. The Interstitial Cystitis Clinical Trials Group (ICCTG) was subsequently established to conduct randomized clinical trials beginning in 1996. In 2003, this group became the Interstitial Cystitis Collaborative Research Network (ICCRN) and carried out additional randomized clinical trials. In 1998, the Chronic Prostatitis Cohort (CPC) study began to prospectively collect patient data to systematically examine the demographics, clinical characteristics and natural history of CP/CPPS. The NIDDK subsequently initiated the Chronic Prostatitis Collaborative Research Network (CPCRN) which performed clinical trials for CP/CPPS. Results from these clinical research studies failed to identify definitive risk factors or generally effective treatments, with the exception of a single study suggesting that myofascial physical therapy might be effective in IC/BPS. The NIDDK-supported Boston Area Community Health (BACH) Survey and the RAND IC Epidemiology (RICE) Study provided estimates on the prevalence of IC-related symptoms for both men and women, as well as an expanded understanding of symptom morbidity. In addition to these clinical and epidemiological studies, many basic research efforts were developed to describe pathophysiology at the cellular level, including in vivo studies of model systems. However, no consensus agreement has been achieved on an underlying etiology for UCPPS, though co-occurrence of UCPPS with other chronic non-urologic pain syndromes has been revealed.

3In light of the limitations of previous studies and results showing potential associations between UCPPS and other chronic pain conditions, the NIDDK proposes that the traditional bladder and prostate centered focus of UCPPS research be broadened to a systemic view of disease in which the interplay between the genitourinary system and other physiological systems (e.g., the central nervous system), is highlighted. In addition, it is suggested that studies of UCPPS would benefit from incorporating broad approaches involving a diversity of urologic and non-urologic disciplines to promote a more comprehensive characterization of patient phenotype.

4These concepts, as well as recommendations solicited from the scientific community, prompted the NIDDK to initiate a new research program for the study of UCPPS, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. Since its inception in 2008, the MAPP Research Network has adopted a highly collaborative and integrated research strategy that incorporates new and novel approaches conducted by investigators representing traditional urologic disciplines and broad non-urologic expertise, including experts in pain research, neurobiology and neuroimaging, infectious disease, biomarker discovery, animal modeling, epidemiology, psychology, immunology, among many others. The overarching goal of the MAPP Research Network is to provide findings useful for designing future clinical trials and ultimately to improve clinical management for UCPPS patients. Importantly, the design and goals of the MAPP Network are complementary to other large phenotyping efforts for non-urologic pain conditions being conducted, such as the OPPERA study.

5The MAPP Research Network includes six Discovery Sites and several specialized sub-sites that conduct multiple, collaborative Trans-MAPP (i.e., across sites) studies, as well as a number of single-site studies, and two specialized Cores (see Acknowledgement for complete listing of MAPP Network Sites and affiliated personnel). The Data Coordination Core (DCC) serves as the central site for data acquisition and storage; provides bio-statistical analyses for all studies; and promotes network-wide quality assurance. The DCC also provides administrative support, including development and maintenance of a public website (http://www.mappnetwork.org/). The Tissue Analysis and Technology Core (TATC) monitors biosample collection and provides sample banking, annotation, and distribution services.

6The MAPP Research Network is currently conducting complementary basic, translational, and clinical science studies to investigate questions of significant clinical relevance and adopts the view that UCPPS potentially involves significant systemic contributions. The primary scientific protocol is a prospective observational study of the treated natural history UCPPS, the Trans-MAPP Epidemiology/Phenotyping (EP) Study. A full description of the central Trans-MAPP EP Study and the complement of urologic and non-urologic measures employed are described in the companion report by Landis et al.. In addition to the extensive phenotyping, the Trans-MAPP EP Study also provide a source of highly characterized participants for further phenotyping through other integrated network protocols. Assembled network working groups develop and conduct complementary Trans-MAPP studies that broadly address potential contributions of various physiological systems and hypotheses of underlying etiology, pathophysiology, risk, and relationships between UCPPS and commonly associated non-urologic syndromes. These include structural and functional assessments of the central nervous system; efforts to uncover potential contributions of infectious agents to etiology; discovery efforts to identify new biological markers; extensive characterizations of symptom variation (e.g., flares); and efforts to develop new and more informative patient reported outcome measures. The network is also engaged in collaborative research to establish and assess animal models validated for the presence of clinically-relevant phenotypes, thus allowing for improved translation between animal and human studies. The MAPP study will provide comprehensive, state-of-the-art phenotyping data which will set the standard for future UCPPS research. Results from the MAPP study can be integrated with other, more clinically focused phenotyping efforts (such as the UPOINT system) to better define the ‘minimal data set’ required to provide optimal patient care for UCPPS patients.

7Within the MAPP Research Network all clinical Trans-MAPP protocols and site-specific efforts, which primarily serve to pilot test ideas complementary to the collaborative protocols, are highly integrated through their use of shared patients and controls evaluated through standard phenotyping; common biological samples; and a standardized data collection, storage, and analysis strategy. In addition, neuroimaging study parameters are standardized across sites and scan data is centrally managed by the University of California at Los Angeles (UCLA) Center for Neurobiology of Stress (painrepository.org), in close collaboration with UCLA-Laboratory of Neuroimaging (LONI), which has extensive experience in the collection, storage and analysis of large multi-site MRI data sets (loni.usc.edu). In this way diverse findings across protocols may be integrated to allow a detailed characterization of a single UCPPS patient or patient sub-groups. Importantly, these efforts are also generating a unique national resource of highly detailed longitudinal clinical and epidemiological data associated with data from additional, integrated phenotyping studies and linked biological samples, for future use by the wider research community through the NIDDK Data and Sample Repositories (http://www3.niddk.nih.gov/researchprograms/repositories/).

8UCPPS research is clearly at a cross-road in which the traditional basic and clinical scientific strategies are being re-evaluated in light of evolving ideas of UCPPS and recognition of the limitations of previous study designs. The MAPP Research Network was created to address these challenges. Advances from network efforts are expected to provide a more comprehensive understanding of UCPPS pathophysiology, identify clinically relevant patient sub-groups, inform the design of future clinical trials, and ultimately improve clinical care. The unique organization and approach of the MAPP Network may also provide a blueprint for multi-site, multi-disciplinary research in the broader pain field, as well as for those disciplines addressing other disorders with ill-defined pathophysiology.

9J. Quentin Clemens, MD, FACS, MSci,

10Network Chair, 2013-Philip Hanno, MD

11Ziya Kirkali, MD

12John W. Kusek, PhD

13J. Richard Landis, PhD

14M. Scott Lucia, MD

15Chris Mullins, PhD

16Michel A. Pontari, MD

17David J. Klumpp, PhD, Co-Director

18Anthony J. Schaeffer, MD, Co-Director

19Apkar (Vania) Apkarian, PhD

20David Cella, PhD

21Melissa A. Farmer, PhD

22Colleen Fitzgerald, MD

23Richard Gershon, PhD

24James W. Griffith, PhD

25Charles J. Heckman II, PhD

26Mingchen Jiang, PhD

27Laurie Keefer, PhD

28Darlene S. Marko, RN, BSN, CCRC

29Jean Michniewicz

30Todd Parrish, PhD

31Frank Tu, MD, MPH

32Emeran A. Mayer, MD, Co-Director

33Larissa V. Rodríguez, MD, Co-Director

34Jeffry Alger, PhD

35Cody P. Ashe-McNalley

36Ben Ellingson, PhD

37Nuwanthi Heendeniya

38Lisa Kilpatrick, PhD

39Jason Kutch, PhD

40Jennifer S. Labus, PhD

41Bruce D. Naliboff, PhD

42Fornessa Randal

43Suzanne R. Smith, RN, NP

44Karl J. Kreder, MD, MBA, Director

45Catherine S. Bradley, MD, MSCE

46Mary Eno, RN, RA II

47Kris Greiner, BA

48Yi Luo, PhD, MD

49Susan K. Lutgendorf, PhD

50Michael A. O’Donnell, MD

51Barbara Ziegler, BA

52Daniel J. Clauw, MD, Co-Director;

53Network Chair, 2008-2013

54J. Quentin Clemens, MD, FACS, MSci,

55Co-Director; Network Chair, 2013-

56Suzie As-Sanie, MD

57Sandra Berry, MA

58Megan E. Halvorson, BS, CCRP

59Richard Harris, PhD

60Steve Harte, PhD

61Eric Ichesco, BS

62Ann Oldendorf, MD

63Katherine A. Scott, RN, BSN

64David A. Williams, PhD

65Dedra Buchwald, MD, Director

66Niloofar Afari, PhD, Univ. Of California, San Diego

67John Krieger, MD

68Jane Miller, MD

69Stephanie Richey, BS

70Susan O. Ross, RN, MN

71Roberta Spiro, MS

72TJ Sundsvold, MPH

73Eric Strachan, PhD

74Claire C. Yang, MD

75Gerald L. Andriole, MD, Co-Director

76H. Henry Lai, MD, Co-Director

77Rebecca L. Bristol, BA, BS, Coordinator

78Graham Colditz, MD, DrPH

79Georg Deutsch, PhD, Univ. of Alabama at Birmingham

80Vivien C. Gardner, RN, BSN, Coordinator

81Robert W. Gereau IV, PhD

82Jeffrey P Henderson, MD, PhD

83Barry A. Hong, PhD, FAACP

84Thomas M. Hooton, MD, Univ of Miami

85Timothy J. Ness, MD, PhD, Univ. of Alabama at Birmingham

86Carol S. North, MD, MPE, Univ. Texas Southwestern

87Theresa M. Spitznagle, PT, DPT, WCS

88Siobhan Sutcliffe, PhD, ScM, MHS

89J. Richard Landis, PhD, Core Director

90Ted Barrell, BA

91Philip Hanno, MD

92Xiaoling Hou, MS

93Tamara Howard, MPH

94Michel A. Pontari, MD

95Nancy Robinson, PhD

96Alisa Stephens, PhD

97Yanli Wang, MS

98M. Scott Lucia, MD, Core Director

99Adrie van Bokhoven, PhD

100Andrea A. Osypuk, BS

101Robert Dayton, Jr

102Karen R. Jonscher, PhD

103Holly T. Sullivan, BS

104R. Storey Wilson, MS

105Garth D.Ehrlich, PhD

106Marsha A. Moses, PhD, Director

107Andrew C. Briscoe

108David Briscoe, MD

109Adam Curatolo, BA

110John Froehlich, PhD

111Richard S. Lee, MD

112Monisha Sachdev, BS

113Keith R. Solomon, PhD

114Hanno Steen, PhD

115Sean Mackey, MD, PhD, Director

116Epifanio Bagarinao, PhD

117Lauren C. Foster, BA

118Emily Hubbard, BA

119Kevin A. Johnson, PhD, RN

120Katherine T. Martucci, PhD

121Rebecca L. McCue, BA

122Rachel R. Moericke, MA

123Aneesha Nilakantan, BA

124Noorulain Noor, BS

125J. Curtis Nickel, MD, FRCSC, Director

126Chris Mullins, PhD

127John W. Kusek, PhD

128Ziya Kirkali, MD

129Tamara G. Bavendam, MD

130BACH: Boston area community health survey; BPS: Bladder pain syndrome; CFS: Chronic fatigue syndrome; CNS: Central nervous system; CPC: Chronic prostatitis cohort; CP/CPPS: Chronic prostatitis/chronic pelvic pain syndrome; DCC: Data coordinating core; DNA: Deoxyribonucleic acid; EEP: External experts panel; FM: Fibromyalgia; IBS: Irritable bowel syndrome; IC/BPS: Interstitial cystitis/bladder pain syndrome; ICCRN: Interstitial cystitis collaborative research network; ICCTG: The interstitial cystitis clinical trials group; ICDB: Interstitial cystitis database study; LONI: Laboratory of neuroimaging; MAPP: Multidisciplinary approach to the study of chronic pelvic pain; MRI/fMRI: Magnetic resonance imaging/functional magnetic resonance imaging; NIDDK: The national institute of diabetes, digestive, and kidney diseases; NUAS: Non-urologic associated syndromes; PPT: Pressure pain threshold; RICE: RAND IC epidemiology study; TATC: Tissue analysis and technology core; Trans-MAPP EP: Trans-MAPP epidemiology and phenotyping study; UCLA: University of california at Los Angeles; UCPPS: Urological chronic pelvic pain syndromes; VB1, VB2: Voided bladder 1, 2

131JQ Clemens, C Mullins, JW Kusek, Z Kirkali, EA Mayer, LV Rodriguez, AJ Schaeffer, D Buchwald, and JR Landis declare no competing interests. DJ Klumpp declares ownership and equity interests in ProbioTx Inc, and Gold Coast Therapeutics Inc. KJ Kreder is a Consultant for Medtronic, Astellas, Symptelligence, and Tengion. GL Andriole is a Consultant for Augmenix, Bayer, Genomic Health, GlaxoSmithKline and Myriad Genetics and has received research grants from Johnson & Johnson, Medivation and Wilex. MS Lucia declares ownership of 3D Biopsy and has consulted for Myriad Genetics and Bayer Healthcare. DJ Clauw has received grants from Pfizer, Cerephex, Lilly, Merck, Nuvo and Furest, and Consulting Fees and Honoraria from Pfizer, Cerephex, Lilly, Merck, Nuvo, Furest, Tonix, Purdue, Therauance, and Johnson & Johnson.

132JQC wrote the initial draft manuscript. All authors read and approved the final manuscript.

133The pre-publication history for this paper can be accessed here:

134http://www.biomedcentral.com/1471-2490/14/57/prepub